Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prostate-specific membrane antigen chimeric antigen receptor natural killer cells
- Development stage
- Unknown
- Lead developer
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Prostate-specific membrane antigen (PSMA) chimeric antigen receptor (CAR) natural killer (NK) cells are an investigational allogeneic cell therapy being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). These engineered NK cells are designed to express a chimeric antigen receptor that specifically targets PSMA, a cell-surface protein highly overexpressed in prostate cancer cells. Upon binding to PSMA, the CAR-NK cells are activated to selectively induce tumor cell lysis and secrete cytotoxic cytokines such as interferon-gamma (IFN-γ), promoting anti-tumor immune responses. Early clinical evaluation in a Phase 1 trial has demonstrated a favorable safety profile with no instances of cytokine release syndrome (CRS) or graft-versus-host disease (GvHD), alongside preliminary evidence of clinical efficacy, including reductions in prostate-specific antigen (PSA) levels.
- Other names
- PSMA CAR-NK cellsPSMA-CAR NK cellsPSMA-targeted CAR-NK cellsallogeneic anti-PSMA CAR-NK cells
02
Targets
CD244 (Natural killer cell receptor 2B4)NKG2D (Natural killer group 2 member D receptor)PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on prostate-specific membrane antigen chimeric antigen receptor natural killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prostate-specific membrane antigen chimeric antigen receptor natural killer cells.